# US 2019/0314337 A1 · Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314337 A1
- Document ID: US20190314337A1
- Status: Published application
- Kind: A1
- Application number: 16/468,782
- Filed: 2017-12-14
- Published: 2019-10-17
- Earliest claimed: 2016-12-14
- Assignees: SK Biopharmaceuticals Co., Ltd.
- Applicants: SK Biopharmaceuticals Co., Ltd.
- Inventors: Yu Jin SHIN; Sei Myoung HAN
- Web page: https://patentgrep.com/patent/US20190314337A1

## CPC

- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a use for the purpose of preventing, alleviating, or treating bipolar disorder by administering a pharmaceutical composition comprising a carbamate compound of the following chemical formula 1.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method for preventing, alleviating or treating bipolar disorder in a subject, comprising administering to the subject a therapeutically effective amount of a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof:
wherein,
R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and
one of A1 and A2 is CH, and the other is N.

### Claim 16 (depends on 15)

The method according to claim 15, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen and C1-C8 alkyl.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the carbamate compound of Formula 1 is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester of the following Formula 2:

### Claim 18 (depends on 15)

The method according to claim 15, wherein the method is for the prevention, alleviation or treatment of mania of bipolar disorder.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the bipolar disorder is one or more selected from the group consisting of bipolar disorder Type I, bipolar disorder Type II, cyclothymic disorder and bipolar disorder not otherwise classified.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the subject is a mammal.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the mammal is a human.

### Claim 22 (depends on 15)

The method according to claim 15, wherein the therapeutically effective amount of the carbamate compound of Formula 1 is 50 mg to 500 mg based on the free form.

### Claim at position 10

23-28. (canceled)
